VACCINE SALES.

VACCINE SALES. MEG TIRRELL SPOKE WITH THE CEO

MEG TIRRELL SPOKE WITH THE CEO

MEG TIRRELL SPOKE WITH THE CEO EARLIER AND JOINS US WITH THE

EARLIER AND JOINS US WITH THE

EARLIER AND JOINS US WITH THE KEY TAKEAWAYS.

KEY TAKEAWAYS.

KEY TAKEAWAYS. MEG.

MEG.

MEG. >> HEY, WILF

>> HEY, WILF

>> HEY, WILF IT WAS A BIG QUARTER FOR PFIZER

IT WAS A BIG QUARTER FOR PFIZER

IT WAS A BIG QUARTER FOR PFIZER MAINLY DRIVEN BY THEIR COVID-19

MAINLY DRIVEN BY THEIR COVID-19

MAINLY DRIVEN BY THEIR COVID-19 VACCINE.

VACCINE.

VACCINE. FORECASTING $26 BILLION IN SALES

FORECASTING $26 BILLION IN SALES

FORECASTING $26 BILLION IN SALES IN 2021.

IN 2021.

IN 2021. THAT'S UP FROM A FORECAST OF $15

THAT'S UP FROM A FORECAST OF $15

THAT'S UP FROM A FORECAST OF $15 BILLION PREVIOUSLY

BILLION PREVIOUSLY

BILLION PREVIOUSLY THE COMPANY ALSO LAYING OUT KEY

THE COMPANY ALSO LAYING OUT KEY

THE COMPANY ALSO LAYING OUT KEY MILESTONES FOR THE VACCINE THIS

MILESTONES FOR THE VACCINE THIS

MILESTONES FOR THE VACCINE THIS YEAR INCLUDING FILING FOR FULL

YEAR INCLUDING FILING FOR FULL

YEAR INCLUDING FILING FOR FULL APPROVAL LATER THIS MONTH AND

APPROVAL LATER THIS MONTH AND

APPROVAL LATER THIS MONTH AND DATA FOR BOOSTER SHOTS, DATA ON

DATA FOR BOOSTER SHOTS, DATA ON

DATA FOR BOOSTER SHOTS, DATA ON PREGNANT WOMEN, DATA GOING DOWN

PREGNANT WOMEN, DATA GOING DOWN

PREGNANT WOMEN, DATA GOING DOWN IN KIDS OF YOUNGER AGES, DOWN TO

IN KIDS OF YOUNGER AGES, DOWN TO

IN KIDS OF YOUNGER AGES, DOWN TO AGES 6 MONTHS TOWARD THE END OF

AGES 6 MONTHS TOWARD THE END OF

AGES 6 MONTHS TOWARD THE END OF THE YEAR

THE YEAR

THE YEAR WE HAD ASK THE CEO WHAT

WE HAD ASK THE CEO WHAT

WE HAD ASK THE CEO WHAT DIFFERENCE IT MAKES TO GET FULL

DIFFERENCE IT MAKES TO GET FULL

DIFFERENCE IT MAKES TO GET FULL APPROVAL OF THE VACCINE VERSUS

APPROVAL OF THE VACCINE VERSUS

APPROVAL OF THE VACCINE VERSUS EMERGENCY USE AUTHORIZATION

EMERGENCY USE AUTHORIZATION

EMERGENCY USE AUTHORIZATION WHICH IS WHAT THEY HAVE NOW.

WHICH IS WHAT THEY HAVE NOW.

WHICH IS WHAT THEY HAVE NOW. HERE'S WHAT HE SAID.

HERE'S WHAT HE SAID.

HERE'S WHAT HE SAID. >> WE CANNOT JUST GIVE IT TO

>> WE CANNOT JUST GIVE IT TO

>> WE CANNOT JUST GIVE IT TO EMPLOYERS OR TO CVS PRIVATELY OR

EMPLOYERS OR TO CVS PRIVATELY OR

EMPLOYERS OR TO CVS PRIVATELY OR TO OTHER VACCINATION SITES OR

TO OTHER VACCINATION SITES OR

TO OTHER VACCINATION SITES OR THE PHYSICIANS CANNOT USE IT IN

THE PHYSICIANS CANNOT USE IT IN

THE PHYSICIANS CANNOT USE IT IN THEIR PRACTICES.

THEIR PRACTICES.

THEIR PRACTICES. IF YOU GET FULL AUTHORIZATION,

IF YOU GET FULL AUTHORIZATION,

IF YOU GET FULL AUTHORIZATION, THOSE CHANNELS ARE GOING TO

THOSE CHANNELS ARE GOING TO

THOSE CHANNELS ARE GOING TO OPEN

OPEN

OPEN >> HE NOTED, THOUGH, THAT RIGHT

>> HE NOTED, THOUGH, THAT RIGHT

>> HE NOTED, THOUGH, THAT RIGHT NOW GOVERNMENTS ARE STILL

NOW GOVERNMENTS ARE STILL

NOW GOVERNMENTS ARE STILL SHOWING A LOT OF INTEREST IN THE

SHOWING A LOT OF INTEREST IN THE

SHOWING A LOT OF INTEREST IN THE VACCINE SO THAT COULD BE A KEY

VACCINE SO THAT COULD BE A KEY

VACCINE SO THAT COULD BE A KEY PURCHASER GOING FORWARD EVEN IF

PURCHASER GOING FORWARD EVEN IF

PURCHASER GOING FORWARD EVEN IF THEY HAVE FULL APPROVAL WHICH

THEY HAVE FULL APPROVAL WHICH

THEY HAVE FULL APPROVAL WHICH WOULD GIVE THEM FLEXIBILITY ON

WOULD GIVE THEM FLEXIBILITY ON

WOULD GIVE THEM FLEXIBILITY ON HOW THEY SELL THE VACCINE.

HOW THEY SELL THE VACCINE.

HOW THEY SELL THE VACCINE. IN TERMS OF PRESIDENT BIDEN'S

IN TERMS OF PRESIDENT BIDEN'S

IN TERMS OF PRESIDENT BIDEN'S COMMENTS, SETTING NEW GOALS FOR

COMMENTS, SETTING NEW GOALS FOR

COMMENTS, SETTING NEW GOALS FOR VACCINATIONS IN THE U.S. JUST

VACCINATIONS IN THE U.S. JUST

VACCINATIONS IN THE U.S. JUST NOW.

NOW.

NOW. AIMING FOR JULY 4th, SEEING 160

AIMING FOR JULY 4th, SEEING 160

AIMING FOR JULY 4th, SEEING 160 MILLION PEOPLE FULLY VACCINATED

MILLION PEOPLE FULLY VACCINATED

MILLION PEOPLE FULLY VACCINATED BY THAT DATE

BY THAT DATE

BY THAT DATE NOW, AIMING FOR THAT GOAL, IF WE

NOW, AIMING FOR THAT GOAL, IF WE

NOW, AIMING FOR THAT GOAL, IF WE STAYED ON THE SAME TRACK THAT

STAYED ON THE SAME TRACK THAT

STAYED ON THE SAME TRACK THAT WE'RE ON NOW, WHICH IS ABOUT 1.3

WE'RE ON NOW, WHICH IS ABOUT 1.3

WE'RE ON NOW, WHICH IS ABOUT 1.3 TO 1.4 MILLION SHOTS PER DAY, WE

TO 1.4 MILLION SHOTS PER DAY, WE

TO 1.4 MILLION SHOTS PER DAY, WE COULD ACTUALLY GET THERE BY JUNE

COULD ACTUALLY GET THERE BY JUNE

COULD ACTUALLY GET THERE BY JUNE 12th, ACCORDING TO OUR DATA

12th, ACCORDING TO OUR DATA

12th, ACCORDING TO OUR DATA ANALYSIS

ANALYSIS

ANALYSIS SO THIS GOAL ACTUALLY IMPLIES

SO THIS GOAL ACTUALLY IMPLIES

SO THIS GOAL ACTUALLY IMPLIES THAT WE WILL STILL CONTINUE TO

THAT WE WILL STILL CONTINUE TO

THAT WE WILL STILL CONTINUE TO SEE A SLOWING IN THE PACE OF

SEE A SLOWING IN THE PACE OF

SEE A SLOWING IN THE PACE OF VACCINATIONS IN THE U.S. THAT WE

VACCINATIONS IN THE U.S. THAT WE

VACCINATIONS IN THE U.S. THAT WE HAVE ALREADY BEEN SEEING

HAVE ALREADY BEEN SEEING

HAVE ALREADY BEEN SEEING THEY WANT TO SEE 70% OF ADULTS

THEY WANT TO SEE 70% OF ADULTS

THEY WANT TO SEE 70% OF ADULTS VACCINATED WITH AT LEAST ONE

VACCINATED WITH AT LEAST ONE

VACCINATED WITH AT LEAST ONE SHOT BY JULY 4th, GUYS

SHOT BY JULY 4th, GUYS

SHOT BY JULY 4th, GUYS A THRESHOLD AT WHICH POINT WE

A THRESHOLD AT WHICH POINT WE

A THRESHOLD AT WHICH POINT WE MIGHT TO SEE MAJOR IMPACTS ON

MIGHT TO SEE MAJOR IMPACTS ON

MIGHT TO SEE MAJOR IMPACTS ON HOSPITALIZATION CASES AND DEATHS

HOSPITALIZATION CASES AND DEATHS

HOSPITALIZATION CASES AND DEATHS HERE IN THE COUNTRY.

HERE IN THE COUNTRY.

HERE IN THE COUNTRY. GUYS, BACK TO YOU.

GUYS, BACK TO YOU.

GUYS, BACK TO YOU. >> MEG, I GUESS WE GOT A GLIMPSE

>> MEG, I GUESS WE GOT A GLIMPSE

>> MEG, I GUESS WE GOT A GLIMPSE THIS MORNING WITH PFIZER NOT

THIS MORNING WITH PFIZER NOT

THIS MORNING WITH PFIZER NOT ONLY WITH THE SUCCESS OF THEIR

ONLY WITH THE SUCCESS OF THEIR

ONLY WITH THE SUCCESS OF THEIR ROLLOUT AND PRODUCTION OF THEIR

ROLLOUT AND PRODUCTION OF THEIR

ROLLOUT AND PRODUCTION OF THEIR VACCINE BUT WHAT THEY CHARGE FOR

VACCINE BUT WHAT THEY CHARGE FOR

VACCINE BUT WHAT THEY CHARGE FOR IT AND THE PROFIT MARGIN WHEN

IT AND THE PROFIT MARGIN WHEN

IT AND THE PROFIT MARGIN WHEN YOU COMPARE IT TO ASTRAZENECA

YOU COMPARE IT TO ASTRAZENECA

YOU COMPARE IT TO ASTRAZENECA AND J&J.

AND J&J.

AND J&J. >> YEAH.

>> YEAH.

>> YEAH. WELL, ASTRAZENECA AND J&J ARE

WELL, ASTRAZENECA AND J&J ARE

WELL, ASTRAZENECA AND J&J ARE DOING THIS ON A NOT-FOR-PROFIT

DOING THIS ON A NOT-FOR-PROFIT

DOING THIS ON A NOT-FOR-PROFIT BASIS DURING THE PANDEMIC AND SO

BASIS DURING THE PANDEMIC AND SO

BASIS DURING THE PANDEMIC AND SO YOU'RE NOT SEEING MAJOR NUMBERS

YOU'RE NOT SEEING MAJOR NUMBERS

YOU'RE NOT SEEING MAJOR NUMBERS LIKE YOU'RE SEEING FOR PFIZER.

LIKE YOU'RE SEEING FOR PFIZER.

LIKE YOU'RE SEEING FOR PFIZER. MODERNA REPORTS ON THURSDAY AND

MODERNA REPORTS ON THURSDAY AND

MODERNA REPORTS ON THURSDAY AND WE EXPECT TO SEE AN UPDATED

WE EXPECT TO SEE AN UPDATED

WE EXPECT TO SEE AN UPDATED FORECAST FOR 2021 REVENUE AS

FORECAST FOR 2021 REVENUE AS

FORECAST FOR 2021 REVENUE AS WELL

WELL

WELL SO IT IS QUITE A DIFFERENTIT WIR

SO IT IS QUITE A DIFFERENTIT WIR

SO IT IS QUITE A DIFFERENTIT WIR S